Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. ...
psilocybin may have contributed significantly to the therapeutic effect. lastly, a multi-centric trial investigating efficacy of 25mg, 10mg, and 1mg of psilocybin in patients with treatment-resistant depression reported significant ...
Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and...
ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and non-selective...
Analysis of continuous outcomes used a mixed-effects model for repeated measures with an unstructured covariance matrix, adjusted for the baseline score of the relevant outcome assessment, site, sex, and treatment-resistant depression (TRD) status as fixed effects with no imputation of missing data....
The New England Journal of Medicine publishes results from phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depressionAbout the phase 2b trial Our randomised controlled phase 2b study of investigational psilocybin treatment in treatment-resistant depression is the largest...
A single dose of a synthetic formulation of psilocybin provides rapid improvement in treatment-resistant depression, suggest results from the largest randomized controlled study of psilocybin to date.
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep. 2024;14(1):2929. doi:10.1038/s41598-024-53188-9 PubMedGoogle ScholarCrossref 37. Carhart-Harris RL, Roseman L, Haijen E, et al. Psychedelics and...
L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619–627 (2016). A paper reporting that psilocybin alleviates depression in treatment-resistant patients. Article PubMed Google Scholar Roseman, L. et al. The...
Food and Drug Administration (FDA) approved esketamine nasal spray for treatment-resistant depression therapy [16]. Psilocybin (3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate) is a natural substance present in Grophoriacees mushrooms, genus psilocybe [17]. Psilocybin is a prodrug ...